Newsbenzinga
Immunic Says Open-Label Extension Data Support Durability Of Vidofludimus Calcium Disability Outcomes In Phase 2 Progressive MS Trial
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…